

Call for Papers

Neuroimaging Biomarkers in Psychotic Disorders



© Andrew Brookes / Connect Images / Getty Images

This collection highlights neuroimaging studies that identify biomarkers across the psychosis spectrum, encompassing schizophrenia, schizoaffective and related disorders. By integrating structural MRI, MRS, functional connectivity, diffusion imaging and PET, it seeks work linking brain measures to symptoms, cognition and clinical trajectories. Submissions may employ multimodal approaches, advanced analytic pipelines, machine-learning classification or network neuroscience to uncover neural signatures predictive of onset, progression or treatment response. Emphasis is on translational potential: establishing reproducible imaging markers that inform early detection, prognosis and personalized interventions for individuals with psychotic presentations.

We welcome articles leveraging neuroimaging modalities – structural, functional, diffusion and molecular (including PET and MRS) – to define reliable biomarkers in psychotic disorders. Topics include gray matter morphometry, functional connectivity of default-mode, salience and fronto-striatal networks, PET ligand studies of neurotransmitter systems, MRS studies of neurometabolites, DTI tractography, and machine-learning models predicting clinical or cognitive outcomes. Contributions addressing reproducibility, large-scale or multicenter datasets, longitudinal designs and integration with genetic, neurochemical or behavioral data are particularly encouraged to bridge neuroscience insights and clinical application.

Topics of particular interest include, but are not limited to:

- Reproducibility of neurophenotype (brain-behavior) associations
- The role of neuroimaging in mechanistic and pharmacological studies
- Longitudinal imaging and the importance of temporal dynamics in disease mechanisms
- Integrating multimodal data to advance neural markers of disease
- The emerging role of AI in defining neuroimaging markers of psychotic disorders

Guest Editors

Alan Anticevic, PhD, Johnson & Johnson Innovative Medicine, United States

Kun Yang, PhD, Johns Hopkins University, United States

This Collection supports and amplifies research related to [SDG 3 \(Good Health and Well-being\)](#).



SPRINGER NATURE GROUP
SDG Programme
supporting the Sustainable Development Goals



Please [click here](#) or scan the QR code to visit our website.
Submission Deadline: **24 November 2026**